Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by stargazer1on Dec 27, 2023 12:10pm
277 Views
Post# 35801262

NO ONE ELSE HAS A DRUG TO REPAIR CRUSED, SEVERED NEURONS

NO ONE ELSE HAS A DRUG TO REPAIR CRUSED, SEVERED NEURONSIf our drug works, AND IT WORKED ON ANIMALS, well people say that I'm an animal, they do call me a pig, so that means that it will work on people? Well, whatever, ALL INDICATIONS are that it will work on people, and our volume this morning is already 139,000 shares (average is 43,000 traded daily)

So something could be in the wind, and that's not me passing, umm, gas. Nope, this stock doesn't smell. 

139,000 shares, all while the stock moves higher and higher. Look at our year's chart. Spiling straight up. WAY ABOVE WHAT IF HAS BEEN ALL YEAR LONG. WAAAYYY ABOVE OUR PREVIOUS PRICE.

TODAY IT IS TIME TO BUY. IT LOOKS LIKE A PRESS RELEASE IS TO BE RELEASED. I'VE BEEN BUYING BEFORE THAT HAPPENS! NO GUARENTEE, BUT THINGS ARE SURE POINTING THAT WAY. 

You might consider buying some here. A chance like this comes once in a purple moon. .. That's a blue moon during a red sunset after a large volcano has saturated the atmosphere with its gas. Very rare.
<< Previous
Bullboard Posts
Next >>